康莱特注射液辅助治疗在晚期非小细胞肺癌患者中的临床疗效  

Clinical Effect of Kanglaite Injection in Treatment of Patients with Advanced Non-Small Cell Lung Cancer

作　　者：石磊 任云会[1] 杨丽[1] SHI Lei;REN Yunhui;YANG Li(Longnan Hospital,Daqing,Heilongjiang 163453,China)

机构地区：[1]大庆龙南医院,黑龙江大庆163453

出　　处：《大医生》2019年第12期107-108,共2页Doctor

摘　　要：目的研究康莱特注射液辅助治疗在晚期非小细胞肺癌患者中的临床疗效。方法选取2017年3月至2019年3月大庆龙南医院收治的晚期非小细胞肺癌患者54例,根据入院时间分为单纯化疗组与康莱特注射液组,各27例。其中对单纯化疗组患者采取单纯化疗治疗,而对康莱特注射液组患者采取化疗辅助康莱特注射液进行治疗。比较两组患者的症状缓解率以及临床受益疗效。结果康莱特注射液组患者的症状缓解率及临床受益疗效明显高于单纯化疗组,差异有统计学意义(P<0.05)。结论康莱特注射液辅助治疗在晚期非小细胞肺癌患者中的临床应用效果显著,值得进一步推广与使用。Objective To study the clinical effect of Kanglaite Injection in the treatment of advanced nonsmall cell lung cancer(NSCLC).Methods A total of 54 patients with advanced NSCLC admitted to our hospital from March 2017 to March 2019 were selected and divided into the chemotherapy group(27 cases)and the Kanglaite Injection group(27 cases)according to the time of admission.Among them,patients in the chemotherapy group were treated with chemotherapy alone,while patients in the Kanglaite Injection group were treated with chemotherapy-assisted Kanglaite Injection.The symptom remission rate and clinical benefit o fthe two groups were compared.Results The symptom remission rate and clinical benefit were better in the Kanglaite Injection group than those in the chemotherapy group(P<0.05).Conclusion The clinical effect of Kanglaite Injection in the treatment of advanced NSCLC patients was significant,and it is worthy of further promotion and use.

关 键 词：康莱特注射液 辅助治疗 晚期非小细胞肺癌 

分 类 号：R73[医药卫生—肿瘤]